玻璃体黄斑粘连或玻璃体黄斑牵拉可能影响抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性的效果
本综述系统检索多个数据库至2016年6月30日,纳入9项研究共2212例参与者,评估玻璃体黄斑粘连(VMA)或玻璃体黄斑牵拉(VMT)对新生血管性年龄相关性黄斑变性(nAMD)抗血管内皮生长因子(anti-VEGF)治疗结局的影响。结果显示,第6个月时VMA/VMT(+)组最佳矫正视力(BCVA)平均改善和中心视网膜厚度(CRT)平均下降均少于VMA/VMT(-)组;第12个月时两组差异较小或仅边缘显著;12个月内VMA/VMT(+)组需要更多注射。作者认为临床医生应考虑到合并VMA或VMT可能在治疗早期拮抗anti-VEGF药物的疗效。
要点
- 第6个月时VMA/VMT(+)组BCVA平均改善少于VMA/VMT(-)组(95%CI -3.05至-0.96个字母,p=0.0002)。
- 第6个月时VMA/VMT(+)组CRT平均下降少于VMA/VMT(-)组(95%CI 15.53至32.98 μm,p<0.00001)。
- 12个月内VMA/VMT(+)组需要更多注射(95%CI 0.25至0.95,p=0.0008)。
核心结论
- 使用anti-VEGF药物治疗nAMD时,临床医生应考虑到合并VMA或VMT可能在治疗早期拮抗anti-VEGF药物的疗效。
研究设计与样本
- 系统综述,检索Pubmed.gov、Cochrane Library、Web of Science、中国国家知识基础设施、万方、SinoMed和ClinicalTrials.gov至2016年6月30日,最终纳入9项研究共2212例参与者。
主要发现
- 第6个月时VMA/VMT(+)组BCVA平均改善少于VMA/VMT(-)组(95%CI -3.05至-0.96个字母,p=0.0002)。
- 第6个月时VMA/VMT(+)组CRT平均下降少于VMA/VMT(-)组(95%CI 15.53至32.98 μm,p<0.00001)。
- 第12个月时两组BCVA差异较小或仅边缘显著(95%CI -0.01至2.00个字母,p=0.05)。
- 第12个月时两组CRT差异较小或仅边缘显著(95%CI 0.17至23.7 μm,p=0.05)。
- 12个月内VMA/VMT(+)组需要更多注射(95%CI 0.25至0.95,p=0.0008)。
临床怎么用
- 作者认为,使用anti-VEGF药物治疗nAMD时,临床医生应考虑到合并VMA或VMT可能在治疗早期拮抗anti-VEGF药物的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this review is to determine whether vitreomacular adhesion (VMA) or vitreomacular traction (VMT) has an influence on the outcomes of antivascular endothelium growth factor (anti-VEGF) treatment neovascular age-related macular degeneration (nAMD). METHODS: A systematic literature search was performed in Pubmed.gov, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, SinoMed and ClinicalTrials.gov up to 30 June 2016 to identify eligible studies. RESULTS: Nine studies and 2212 participants were finally identified. At month 6, the mean improvement in best-corrected visual acuity (BCVA) and mean decline in central retinal thickness (CRT) of the VMA/VMT(+) group was less than that of the VMA/VMT(-) group (95% CI -3.05 to -0.96 letters, p=0.0002; 15.53 to 32.98 μm, p<0.00001; respectively); at month 12, there was a small or only marginally significant difference (-0.01 to 2.00 letters, p=0.05; 0.17 to 23.7 μm, p=0.05; respectively) between the groups. During the 12 months, however, the VMA/VMT(+) group required more injections ((0.25 to 0.95), p=0.0008). CONCLUSIONS: In using anti-VEGF drugs to treat nAMD, clinicians should take into account the fact that concurrent VMA or VMT might antagonise the efficacy of anti-VEGF drugs during the early stage of treatment.
引用
- Xie P, Zheng X, Yu Y, et al. Vitreomacular adhesion or vitreomacular traction may affect antivascular endothelium growth factor treatment for neovascular age-related macular degeneration. Br J Ophthalmol. 2017. PMID: 28596285. doi:10.1136/bjophthalmol-2017-310155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。